Based on the hopeful outcomes of treatment with CAR-T and CAR-NK cells targeting CD7 and CD38 markers, as well as the success in vtiro development of nanobody-based CAR-NK cells against these tumor antigens, it seems that nanobody-based CD7 and CD38 CAR-NK cells will advance to clinical stage investigations for the treatment of leukemia, lymphoma, and myeloma. This evidence concerns the gene CD38 and lymphoma.